Q2 FY2026 · ended Jun 30, 2026 · Revenue $105,000, -53.3% YoY · Filed Aug 13, 2026
Cocrystal Pharma, Inc. (COCP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $105,000 and a net loss of $3.2 million. As of Jun 30, 2026 it held $2.2 million in cash and investments and $1.3 million in total debt.
Revenue
$105,000
-53.3% vs prior quarter
Net income
$-3.16M
-54.0% vs year-ago quarter
Operating cash flow
$-2.52M
-16.8% vs year-ago quarter
Free cash flow
$-1.74M
+45.1% vs year-ago quarter
EPS
$-0.23
-15.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
19.26M
+87.8% vs year-ago quarter
Net cash
$827,000
Q2 FY2026
Operating margin
-3032.4%
Q2 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COCP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bothell, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1412486
- Former names
- BIOZONE PHARMACEUTICALS, INC. (until Mar 25, 2014); International Surf Resorts, Inc. (until Mar 4, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $105,000 | $225,000 | — | — | — |
| Operating income | -$3.2M | -$2.4M | -$2.5M | -$2.1M | -$2.1M |
| Net income | -$3.2M | -$2.3M | -$2.4M | -$2.0M | -$2.1M |
| Diluted EPS | -$0.23 | -$0.17 | -$0.18 | -$0.19 | -$0.20 |
| Operating cash flow | -$2.5M | -$2.3M | -$1.7M | -$1.4M | -$2.2M |
| Free cash flow | — | — | -$1.7M | -$1.4M | — |
| Total assets | $4.6M | $7.4M | $9.7M | $10.4M | $8.5M |
| Total liabilities | $3.6M | $3.3M | $3.4M | $2.8M | $3.2M |
| Stockholders' equity | $1.0M | $4.1M | $6.3M | $7.7M | $5.3M |
| Cash and investments | $2.2M | $4.7M | $7.0M | $7.7M | $4.8M |
| Total debt | $1.3M | $1.4M | $1.5M | $1.6M | $1.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 18, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 17, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Aug 3, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 17, 2026 | Jul 14, 2026 |
All 672 Cocrystal Pharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.